サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1631518

酒さ治療の市場規模、シェア、動向分析レポート：薬剤クラス別、投与方法別、地域別、セグメント別予測、2025年～2030年

Rosacea Treatment Market Size, Share & Trends Analysis Report By Drug Class (Antibiotics, Alpha Agonists, Retinoids, Corticosteroids), By Mode Of Administration (Topical, Oral), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
酒さ治療の市場規模、シェア、動向分析レポート：薬剤クラス別、投与方法別、地域別、セグメント別予測、2025年～2030年
出版日: 2024年12月18日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

酒さ治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の酒さ治療市場規模は2030年までに31億2,000万米ドルに達する見込みです。

2025～2030年のCAGRは7.1%を記録すると予測されています。先進的製剤や疾患の高い有病率など、いくつかの要因が市場の成長を促進すると予測されています。

酒さは世界中で4億人以上が罹患しており、成人における世界の罹患率は5%と推定されています。治療を受けている患者は150万人以下であり、診断が非常に遅れている疾患です。この疾患は男性よりも女性の発症率が高く、いくつかの研究では酒さと更年期障害との関連性が指摘されています。絶対的な治療法が確立されていないため、治療法の選択肢は病気の管理に集中しています。

酒さ治療の市場は、複数の特許切れによりジェネリック医薬品が主流となっており、非常に細分化された治療状況となっています。酒さは過小診断されやすい疾患であり、ニキビと誤診されることも多いです。治療の適応外使用は、酒さに特化した治療において激しい競合を引き起こしています。

局所療法は依然として治療の主流です。外用製品は2017年に60％以上の市場シェアを獲得しました。予測期間中、局所製品は経口薬に対するリードを維持すると予想されるが、併用製品への傾斜の高まりに支えられ、市場はパラダイムシフトを目の当たりにしています。

酒さ治療の選択肢としては、抗生物質、α作動薬、レチノイド、免疫抑制剤、コルチコステロイド、降圧剤などがあります。抗生物質は治療の第一選択薬として配合され、2017年には薬剤クラス別で優位を占めており、この傾向は2025年まで続くと予想されます。

酒さ治療市場の成長は、Rhofade、Mirvaso、Oracea、MetroGel、Noritate、Finaceaなどの主要製品の好調な商業的売上に支えられています。ジェネリック医薬品の浸透が抑制要因となっているもの、有望なパイプライン製品の発売が間近に迫っていることから、世界市場の将来は楽観的です。

酒さ治療市場レポートハイライト

  • 酒さの第一選択薬としての役割が確立されているため、2024年の売上シェアは抗生物質セグメントが51.3%で市場を独占しました。
  • 局所療法セグメントは2024年に最大の収益シェアを占め、市場を独占しました。
  • 北米の酒さ治療市場は、2024年に38.7%の最も高い売上シェアを占めたが、これは消費者の高い認知度や先進医療インフラなどの複合的な要因によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 酒さ治療市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析

第4章 酒さ治療市場：薬剤クラスビジネス分析

  • 薬剤クラス市場シェア、2024年と2030年
  • 薬剤クラスセグメントダッシュボード
  • 市場規模と予測と動向分析、薬剤クラス別、2018～2030年
  • 抗生物質
  • アルファ作動薬
  • レチノイド
  • コルチコステロイド
  • 免疫抑制剤
  • その他

第5章 酒さ治療市場：投与方法ビジネス分析

  • 投与方法市場シェア、2024年と2030年
  • 投与方法セグメントダッシュボード
  • 市場規模と予測と動向分析、投与方法別、2018～2030年
  • 局所
  • 経口

第6章 酒さ治療市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 市場規模と予測動向分析、2018～2030年
  • 北米
    • 国別、2018～2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別、2018～2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • AbbVie Inc.
    • Bayer AG
    • Bausch Health Companies Inc.
    • Nestle Skin Health
    • Sol-Gel Technologies Ltd.
    • Mayne Pharma Group Limited
    • LEO Pharma A/S
    • Pfizer Inc.
    • Aclaris Therapeutics, Inc.
    • Galderma
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global rosacea treatment market, by region, 2018 - 2030 (USD Billion)
  • Table 4 Global rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 5 Global rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 6 North America rosacea treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 7 North America rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 8 North America rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 9 U.S. rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 10 U.S. rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 11 Canada rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 12 Canada rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 13 Mexico rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 14 Mexico rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 15 Mexico rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 16 Europe rosacea treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 17 Europe rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 18 Europe rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 19 UK rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 20 UK rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 21 Germany rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 22 Germany rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 23 France rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 24 France rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 25 Italy rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 26 Italy rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 27 Spain rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 28 Spain rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 29 Norway rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 30 Norway rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 31 Denmark rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 32 Denmark rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 33 Sweden rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 34 Sweden rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 35 Asia Pacific rosacea treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 36 Asia Pacific rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 37 Asia Pacific rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 38 Japan rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 39 Japan rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 40 China rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 41 China rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 42 India rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 43 India rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 44 Australia rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 45 Australia rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 46 South Korea rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 47 South Korea rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 48 Thailand rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 49 Thailand rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 50 Latin America rosacea treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 51 Latin America rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 52 Latin America rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 53 Brazil rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 54 Brazil rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 55 Argentina rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 56 Argentina rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 57 Middle East & Africa rosacea treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 58 Middle East & Africa rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 59 Middle East & Africa rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 60 South Africa rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 61 South Africa rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 62 Saudi Arabia rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 63 Saudi Arabia rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 64 UAE rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 65 UAE rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)
  • Table 66 Kuwait rosacea treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 67 Kuwait rosacea treatment market, by mode of administration, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Rosacea treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug class outlook (USD Billion)
  • Fig. 10 Mode of administration outlook (USD Billion)
  • Fig. 11 Competitive landscape
  • Fig. 12 Rosacea treatment market dynamics
  • Fig. 13 Rosacea treatment market: Porter's five forces analysis
  • Fig. 14 Rosacea treatment market: PESTLE analysis
  • Fig. 15 Rosacea treatment market: Drug class segment dashboard
  • Fig. 16 Rosacea treatment market: Drug class market share analysis, 2024 & 2030
  • Fig. 17 Antibiotics market, 2018 - 2030 (USD Billion)
  • Fig. 18 Alpha agonists market, 2018 - 2030 (USD Billion)
  • Fig. 19 Retinoids market, 2018 - 2030 (USD Billion)
  • Fig. 20 Corticosteroids market, 2018 - 2030 (USD Billion)
  • Fig. 21 Immunosuppressants market, 2018 - 2030 (USD Billion)
  • Fig. 22 Others market, 2018 - 2030 (USD Billion)
  • Fig. 23 Rosacea treatment market: Mode of administration segment dashboard
  • Fig. 24 Rosacea treatment market: Mode of administration market share analysis, 2024 & 2030
  • Fig. 25 Topical market, 2018 - 2030 (USD Billion)
  • Fig. 26 Oral market, 2018 - 2030 (USD Billion)
  • Fig. 27 Rosacea treatment market revenue, by region
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 North America rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 30 U.S. country dynamics
  • Fig. 31 U.S. rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 32 Canada country dynamics
  • Fig. 33 Canada rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 34 Mexico country dynamics
  • Fig. 35 Mexico rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 36 Europe rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 37 UK country dynamics
  • Fig. 38 UK rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 39 Germany country dynamics
  • Fig. 40 Germany rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 41 France country dynamics
  • Fig. 42 France rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 43 Italy country dynamics
  • Fig. 44 Italy rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 45 Spain country dynamics
  • Fig. 46 Spain rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 47 Norway country dynamics
  • Fig. 48 Norway rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 49 Denmark country dynamics
  • Fig. 50 Denmark rosacea treatment market, 2018 - 2030 (USD Billion
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 53 Asia Pacific rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 54 Japan country dynamics
  • Fig. 55 Japan rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 56 China country dynamics
  • Fig. 57 China rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 58 India country dynamics
  • Fig. 59 India rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 64 Thailand country dynamics
  • Fig. 65 Thailand rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 66 Latin America rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 67 Brazil country dynamics
  • Fig. 68 Brazil rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 69 Argentina country dynamics
  • Fig. 70 Argentina rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 71 MEA rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 72 South Africa country dynamics
  • Fig. 73 South Africa rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 74 Saudi Arabia country dynamics
  • Fig. 75 Saudi Arabia rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 76 UAE country dynamics
  • Fig. 77 UAE rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 78 Kuwait country dynamics
  • Fig. 79 Kuwait rosacea treatment market, 2018 - 2030 (USD Billion)
  • Fig. 80 Company categorization
  • Fig. 81 Company market position analysis
  • Fig. 82 Strategic framework
目次
Product Code: GVR-2-68038-739-1

Rosacea Treatment Market Growth & Trends:

The global rosacea treatment market size is expected to reach USD 3.12 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 7.1% from 2025 to 2030. Several factors such as an advanced formulations and high prevalence of the disease are forecasted to fuel the market growth.

Rosacea affects more than 400 million people worldwide and the global incidence among adults is estimated at 5%. Less than 1.5 million patients seek treatment, making it a highly underdiagnosed condition. This disease has a higher incidence in women than men, with several studies claiming a possible association between rosacea and menopause. In the absence of an absolute cure, treatment options are largely focused on management of the disease.

The market for rosacea treatment is majorly genericized due to multiple patent expiries, leading to a highly fragmented therapeutic landscape. Rosacea is an underdiagnosed condition and is frequently misdiagnosed as acne. Off-label use of therapeutics pose an intensely competitive space for rosacea-specific treatments.

Topical therapies remain the mainstay for treatment. Topical products captured more than 60% market share in 2017. Although topical items are expected to maintain their lead over oral medicines through the forecast period, the market is witnessing a paradigm shift supported by the increasing inclination towards combination products.

Therapeutic options available for rosacea treatment are antibiotics, alpha agonists, retinoids, immunosuppressants, corticosteroids, antihypertensive agents, and others. Antibiotics are prescribed for the first-line treatment, making them the dominant drug class in 2017-a trend expected to continue through 2025.

The rosacea treatment market growth is supported by strong commercial sales from key products such as Rhofade, Mirvaso, Oracea, MetroGel, Noritate, and Finacea. Although increased penetration of generic drugs is a constraining factor, the impending launch of several promising pipeline products indicate an optimistic future for the global market.

Rosacea Treatments Market Report Highlights:

  • The antibiotics segment dominated the market with a revenue share of 51.3% in 2024 due to their established role as first-line therapies for rosacea.
  • The topical segment dominated the market with the largest revenue share in 2024, which can be attributed to its convenience and effectiveness in treating localized symptoms.
  • North America rosacea treatment market held the highest revenue share of 38.7% in 2024 due to a combination of factors, including high consumer awareness and advanced healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Mode of Administration
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rosacea Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Rosacea Treatment Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Billion)
  • 4.4. Antibiotics
    • 4.4.1. Antibiotics Market, 2018 - 2030 (USD Billion)
  • 4.5. Alpha Agonists
    • 4.5.1. Alpha Agonists Market, 2018 - 2030 (USD Billion)
  • 4.6. Retinoids
    • 4.6.1. Retinoids Market, 2018 - 2030 (USD Billion)
  • 4.7. Corticosteroids
    • 4.7.1. Corticosteroids Market, 2018 - 2030 (USD Billion)
  • 4.8. Immunosuppressants
    • 4.8.1. Immunosuppressants Market, 2018 - 2030 (USD Billion)
  • 4.9. Others
    • 4.9.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 5. Rosacea Treatment Market: Mode of Administration Business Analysis

  • 5.1. Mode of Administration Market Share, 2024 & 2030
  • 5.2. Mode of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Mode of Administration, 2018 to 2030 (USD Billion)
  • 5.4. Topical
    • 5.4.1. Topical Market, 2018 - 2030 (USD Billion)
  • 5.5. Oral
    • 5.5.1. Oral Market, 2018 - 2030 (USD Billion)

Chapter 6. Rosacea Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Rosacea Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Canada Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Europe
    • 6.5.1. Europe Rosacea Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Rosacea Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.7. Latin America
    • 6.7.1. Latin America Rosacea Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.8. MEA
    • 6.8.1. MEA Rosacea Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Rosacea Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AbbVie Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Bayer AG
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Bausch Health Companies Inc.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Nestle Skin Health
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Sol-Gel Technologies Ltd.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Mayne Pharma Group Limited
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. LEO Pharma A/S
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Pfizer Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Aclaris Therapeutics, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Galderma
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives